Press Releases

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) appointments Camille L. Bedrosian, M.D. as an independent member of its board of directors.

Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast. Please see additional details below:

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced financial results for the second quarter ended June 30, 2020 and provided a corporate update.

The orphan drug designation by the FDA for paltusotine to treat acromegaly validates the encouraging clinical data we have seen so far in the Phase 2 ACROBAT Edge clinical trial, and underscores the need for a once daily oral treatment option for patients suffering from this rare disease,” said Michael Monahan, Senior Director of Regulatory Affairs at Crinetics."

28 patients have completed the open-label Edge trial measuring IGF-1 levels after 13 weeks of treatment when patients with acromegaly were switched to once daily oral paltusotine from commercially available depot injections of the peptide somatostatin receptor ligands (SRLs) Recruitment for the Edge and Evolve trials has been completed with 47 and 13 patients, respectively, and topline data is planned for the fourth quarter of 2020. Management expects to use the results for the two trials to support the initiation of Phase 3 clinical development for paltusotine in the first half of 2021